Cargando…

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab

BACKGROUND: Anti-PD-1 agents were approved for advanced melanoma after the landmark trial Checkmate-037. Anti-PD-1 agents can breach immunologic tolerance. Fulminant diabetes is an immune endocrinopathy that results from a violent immune attack leading to complete destruction of pancreatic beta cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chokr, Nora, Farooq, Hafsa, Guadalupe, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830024/ https://www.ncbi.nlm.nih.gov/pubmed/29623227 http://dx.doi.org/10.1155/2018/8981375

Ejemplares similares

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma
por: Teal, Lindsey, et al.
Publicado: (2021)

SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
por: Parikh, Sahil, et al.
Publicado: (2019)

Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
por: Tzoulis, Ploutarchos, et al.
Publicado: (2018)

An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer
por: Naganuma, Ken, et al.
Publicado: (2022)

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
por: Lowe, Jared R., et al.
Publicado: (2016)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021)

A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia
por: Yamamoto, Naoko, et al.
Publicado: (2019)

Nivolumab-induced lichenoid granulomatous stomatitis in a patient with advanced melanoma: A case report
por: Gouveris, P., et al.
Publicado: (2022)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab
por: Tanita, Kayo, et al.
Publicado: (2018)

Fulminant hepatic failure due to metastatic choroidal melanoma
por: Escobar-Valdivia, Emmanuel, et al.
Publicado: (2017)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma
por: Matsubara, Tokuhiro, et al.
Publicado: (2018)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
por: Hantel, Andrew, et al.
Publicado: (2018)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
por: Kuru, Sugabramya, et al.
Publicado: (2017)

Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
por: Samonis, George, et al.
Publicado: (2022)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report
por: Antoniou, Sofia, et al.
Publicado: (2021)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
por: Miyauchi, Masaaki, et al.
Publicado: (2019)

Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis
por: Maeda, Osamu, et al.
Publicado: (2016)

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
por: Furune, Satoshi, et al.
Publicado: (2021)

Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
por: Wix, Sophia, et al.
Publicado: (2023)

Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma
por: Chuang, Jeremy, et al.
Publicado: (2019)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018)

Clinical utility of nivolumab in the treatment of advanced melanoma
por: Asmar, Ramsey, et al.
Publicado: (2016)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
por: Albrecht, Lea Jessica, et al.
Publicado: (2023)

Fatal Fulminant Hepatitis E in a Diabetic Patient on Metformin
por: Peroni, Erika, et al.
Publicado: (2022)

A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
por: Kageyama, Shun-Ichiro, et al.
Publicado: (2016)

Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy
por: Nakamura, Kenta, et al.
Publicado: (2022)

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy
por: Gambichler, Thilo, et al.
Publicado: (2018)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma
por: Fujii, Yosuke, et al.
Publicado: (2017)

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
por: Brokāne, Linda, et al.
Publicado: (2019)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
por: Haikal, Ammar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0t1jms4hc9asj8ppebnv1iboab